GlassScriptPhysician profile
Anthony Aulisio
NPI 1508829805
$10,425.18
in general payments reported to CMS, 2019-2025
41 companies · $1,476 in 2025
The $1,476 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,640 · 2020: $1,015 · 2021: $1,369 · 2022: $1,573 · 2023: $1,613 · 2024: $1,738 · 2025: $1,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,588 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,587.63 |
| Education | $239.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,570.21 | 2019-2025 | Skyrizi, Rinvoq |
| Leo Pharma INC. | $1,200.25 | 2019-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $974.80 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Regeneron Healthcare Solutions, INC. | $920.43 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $806.34 | 2019-2025 | |
| Genzyme Corporation | $709.04 | 2021-2025 | |
| Galderma Laboratories, L.P. | $429.12 | 2019-2025 | Nemluvio, Aklief, Oracea |
| E.R. Squibb & Sons, L.L.C. | $410.32 | 2023-2024 | Sotyktu |
| Pfizer INC. | $304.87 | 2019-2024 | |
| Incyte Corporation | $300.52 | 2021-2024 | Opzelura |
| Dermavant Sciences, INC. | $295.22 | 2022-2024 | Vtama |
| Lilly USA, LLC | $282.67 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $247.26 | 2019-2020 | |
| Ucb, INC. | $241.29 | 2019-2025 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $238.18 | 2019-2023 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Aulisio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.